New heart drug safety checked in small indian study
NCT ID NCT06086353
First seen Nov 20, 2025 · Last updated May 12, 2026 · Updated 21 times
Summary
This study looked at the safety of a medicine called VyndaMx (tafamidis) for people with a rare heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). Six adults in India took the medicine by mouth, and doctors tracked any side effects for 6 months. The goal was to see if the drug is safe for this condition, which causes protein clumps to build up in the heart and weaken its pumping.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AIG Hospital
Hyderabad, 500032, India
-
Max Super Speciality Hospital
New Delhi, 110017, India
-
Sri Jayadeva Institute of Cardiovascular Sciences and Research
Bangalore, Karnataka, 560069, India
Conditions
Explore the condition pages connected to this study.